Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin with R-CHOP or R-CHP as first-line therapy for diffuse large B-cell lymphoma
2015-004741-54Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jan 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (3 arms), sponsored by Seagen Inc. Primary endpoint: Complete remission rate. Started Jan 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2015-004741-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004741-54.